

## Accessibility & Affordability Working Group Member List

<b>AAWG Board Members</b>	<b>Affiliation</b>	<b>Role/Expertise/Advocacy</b>
Maria Bonneville	California Institute for Regenerative Medicine	Vice Chair of the ICOC, Governing Board of CIRM
Kim Barrett	University of California, Davis	ICOC Member
Dan Bernal	University of California, San Francisco	ICOC Member, Patient Advocate – HIV/AIDS
David Higgins	Michael J. Fox Foundation (formerly Parkinson’s Action Network)	ICOC Member, Patient Advocate – Parkinson’s Disease
Vito Imbasciani	California Institute for Regenerative Medicine	Chair of the ICOC, Governing Board of CIRM
Pat Levitt	Children’s Hospital, Los Angeles	ICOC Member
Adriana Padilla	Community Medical Providers	ICOC Member, Patient Advocate, Type II Diabetes
<b>AAWG Members</b>	<b>Affiliation</b>	<b>Role/ Expertise/Advocacy</b>
Elizabeth Boileau	UC Davis Health	Development of key payer strategies across Commercial, Medicare and Medicaid programs, building sustainable value-based programs across all payor types, strengthening key internal relationships
James DeBenedetti	Covered California	An expert or a highly knowledgeable individual with experience in California’s public insurance program (Covered California), and the process for

# C I R M

CALIFORNIA INSTITUTE FOR  
REGENERATIVE MEDICINE

		reimbursement of innovative therapies
Ted Goldstein	Independent Consultant	Individual with private sector experience in innovative therapy medical coverage terms, qualifications and the process for reimbursement
Christina Hartman	Orchard Therapeutics	A representative from patient advocacy organizations with experience in coverage, qualifications, and reimbursement of innovative therapies
Darius Lakdawalla	University of Southern California	A health care economist, with experience in advising or negotiating with private insurers, government insurers, or corporate self-insurance programs on coverage for innovative therapies or human trials, including experience in assisting hospitals and clinics in covering financial gaps in coverage of the direct and indirect costs of innovative therapies
Harlan Levine	City of Hope	Patient navigator with training and experience helping patients obtain financial support from private insurers, public support or nonprofit support and helping

# CIRM

CALIFORNIA INSTITUTE FOR  
REGENERATIVE MEDICINE

		patients obtain social service support
Maheswari Senthil	University of California, Irvine	Representative from hospitals in California that are participating in stem cell clinical trials or FDA approved stem cell or genetic therapy
Adrienne Shapiro	Axis Advocacy	Representative from patient advocacy organizations with experience in coverage, qualifications, and reimbursement of innovative therapies
Ammar Qadan	Cepheid	Expert in federal therapy coverage, qualifications, and process for reimbursement and if possible, Medicare and Medicaid